Experience with a luteinizing hormone-releasing hormone agonist in patients with prostate cancer

Berezin P.G.; Milovanov V.V.; Ivannikov A.A.

doi:https://doi.org/10.17116/onkolog20165229-33

Berezin P.G.

Tambovskiĭ oblastnoĭ onkologicheskiĭ klinicheskiĭ dispanser

Milovanov V.V.

Tambovskiĭ oblastnoĭ onkologicheskiĭ klinicheskiĭ dispanser

Ivannikov A.A.

Tambovskiĭ oblastnoĭ onkologicheskiĭ klinicheskiĭ dispanser

Experience with a luteinizing hormone-releasing hormone agonist in patients with prostate cancer

Authors:

Berezin P.G., Milovanov V.V., Ivannikov A.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2016;5(2): 29‑33

DOI: 10.17116/onkolog20165229-33

Read: 2433 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Berezin PG, Milovanov VV, Ivannikov AA. Experience with a luteinizing hormone-releasing hormone agonist in patients with prostate cancer. P.A. Herzen Journal of Oncology. 2016;5(2):29‑33. (In Russ.)
https://doi.org/10.17116/onkolog20165229-33

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Potential of specialized diet therapy in reducing toxic manifestations in patients with metastatic castration-resistant prostate cancer with bone metastases during radionuclide therapy with radium chloride [223Ra]. P.A. Herzen Journal of Oncology. 2024;(6):33-41

Remote results of treatment of patients with prostate cancer who underwent radiation therapy in a combined version. P.A. Herzen Journal of Oncology. 2025;(3):14-19

Patterns of CAF expression in tumors of the genitourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35

Pathogenetic interrelations of hypogonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23

Diagnostic accuracy of the aging males’ symptoms questionnaire for screening androgen deficiency in patients with psoriatic arthritis. Russian Journal of Preventive Medicine. 2025;(5):27-33

Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medicine. 2025;(7):111-118

Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Federation. Medical Technologies. Assessment and Choice. 2025;(3):83-92

Abstract:

The efficiency of hormone therapy was analyzed in patients with locally advanced or metastatic prostate cancer. Among all the drugs of a group of luteinizing hormone-releasing hormone agonists, leuprorelin acetate showed the best result in suppressing testosterone and PSA levels in urologic oncology practice. A clinical trial was done using different hormone treatment regimens, including orchiectomy, and different leuproprelin acetate therapy regimens. The drug was shown to be effective as compared to other hormone therapy options.

Keywords:

hormone therapy

prostate cancer

luteinizing hormone-releasing hormone agonists

leuprorelin acetate

testosterone

PSA

androgen blockade

Authors:

Berezin P.G.

Tambovskiĭ oblastnoĭ onkologicheskiĭ klinicheskiĭ dispanser

Milovanov V.V.

Tambovskiĭ oblastnoĭ onkologicheskiĭ klinicheskiĭ dispanser

Ivannikov A.A.

Tambovskiĭ oblastnoĭ onkologicheskiĭ klinicheskiĭ dispanser

Close metadata

References:

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC Cancer Base No.10. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed March, 2015.
Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-223. doi:10.1001/archsurg.1941.01210140043004.
Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol. 2000;164:726-729. doi:10.1016/S0022-5347(05)67290-4.
McLeod D, Zinner N, Tomera K et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001;58(5):756-761. doi:10.1016/S0090-4295(01)01342-5.
Wechsel HW, Zerbib M, Pagano F, Coptcoal VJ. Randomized open labeled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol. 1996;30(Suppl. 1):7-14, discussion 19-21. PMID:8977984
Perez-Marreno R, Chu FM, Gleason D et al. A six-month, open-label assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther. 2002;24:1902-1914. doi:10.1016/S0149-2918(02)80087-X.
Chu FM, Jayson M, Dineen MK et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002;168:1199-1203. doi:10.1016/S0022-5347(05)64625-3.
Crawford ED, Sartor O, Chu F et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006;175:533-536. doi:10.1016/S0022-5347(05)00161-8.
American Cancer Society. Facts and figures. Atlanta, Ga, USA: American Cancer Society; 2012. 66p. Available at: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012>.
Kaprin A, Starinskii V, Petrova G, eds. The state of cancer care in Russia in 2012. Moscow: FGBU «MNIOI im. P.A. Gertsena»; 2013:11-16. (In Russ.)
Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68-80. doi:10.1016/j.eururo.2007.09.002.
Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology. 2001;58(2, Suppl. 1):108-113. Available at: http://dx.doi.org/10.1016/s0090-4295(01)01252-3.
Chrisp P, Sorkin EM. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991;1(6):487-509. PMID:1794035
Oefelein MG, Feng A, Scolieri MJ. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021-1024. doi:10.1016/S0090-4295(00)00793-7.
Rohl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol. 1992;26:11-14. doi:10.3109/00365599209180389.
Kaisary AV, Tyrrell CJ, Peeling W et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991;67:502-508. doi:10.1111/j.1464-410X.1991.tb15195.x.
Lin BJ, Chen KK, Chen MT, Chang LS. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management prostatic cancer. Urology. 1994;43:834-837. doi:10.1016/0090-4295(94)90145-7.
Vogelzang NJ, Chodak GW, Soloway VS et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995;46:220-226. doi:10.1016/S0090-4295(99)80197-6.
Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet. 2000;355:1491-1496. doi:10.1016/S0140-6736(00)02163-2.
Alekseev B, Nyushko K. Hormonal treatment of patients with prostate cancer. Onkourologiya. 2007;3:57-62. (In Russ.)
Нюшко К.М., Крашенинников А.А., Головащенко М.П., Каприн А.Д. Гормональная терапия с использованием агонистов и антагонистов лютеинизирующего гормона рилизинг гормона у больных раком предстательной железы. Исследования и практика в медицине. 2014;1(1):69-73. doi:http://dx.doi.org/10.17709/2409-2231-2014-1-1-69-73.
Sokov D, Rusakov I. The effect of agonists of luteinizing hormone releasing hormone on the levels of testosterone and quality of life in patients with locally advanced and advanced prostate cancer. Rossiiskii onkologicheskii zhurnal. 2011;1:33-36. (In Russ.)
Tunn UW. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology. 2011;11:15. doi:10.1186/1471-2490-11-15.
Braeckman J, Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard/Depo-Eligard) for advanced prostate cancer in daily practice: a Belgian prospective noninterventional study. Arch Med Sci. 2014;10(3):477-483. doi:10.5114/aoms.2014.43743.
Матвеев В.Б., Волкова М.И., Купчан Д.З., Гриднева Я.В. Депо-форма лейпрорелин ацетата (Элигард) в лечении рака предстательной железы: что выигрывают пациенты? Онкоурология. 2010;4:68-74. doi:http://dx.doi.org/10.17650/1726-9776-2010-6-4-71-77.